IMT 1012

Drug Profile

IMT 1012

Alternative Names: IMT-1012; IMT-1012 Immunotherapeutic vaccine; OCPM immunotherapeutic vaccine

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Immunotope
  • Developer Duke University; Immunotope
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Ovarian cancer

Most Recent Events

  • 13 Aug 2008 IMT 1012 is still in active development
  • 26 Jun 2007 Phase-I clinical trials in Breast cancer in USA (SC)
  • 26 Jun 2007 Phase-I clinical trials in Ovarian cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top